[go: up one dir, main page]

EE04239B1 - Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine - Google Patents

Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine

Info

Publication number
EE04239B1
EE04239B1 EE9700146A EE9700146A EE04239B1 EE 04239 B1 EE04239 B1 EE 04239B1 EE 9700146 A EE9700146 A EE 9700146A EE 9700146 A EE9700146 A EE 9700146A EE 04239 B1 EE04239 B1 EE 04239B1
Authority
EE
Estonia
Prior art keywords
cell
preparation
binding protein
hydroxylamine derivative
hydroxylamine derivatives
Prior art date
Application number
EE9700146A
Other languages
English (en)
Other versions
EE9700146A (et
Inventor
V�gh L�szl�
Liter�ti Nagy P�ter
Szilbereky Jen�
�r�gdi L�szl�
Jedn�kovits Andrea
Jaszlits L�szl�
B�r� Katalin
M�rv�nyos Ede
Barab�s Mih�ly
Heged�s Erzs�bet
Kor�nyi L�szl�
K�rthy M�ria
Balogh G�bor
Horv�th Ibolya
T�r�k Zsolt
Udvardy Va
Dorm�n Gy�rgy
Medzihradszky D�nes
M�zes Bea
Kov�cs Eszter
Duda Ern�
Farkas Beatrix
Glatz Attila
Original Assignee
Biorex Kutat� �S Fejleszt� Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27270113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04239(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biorex Kutat� �S Fejleszt� Rt. filed Critical Biorex Kutat� �S Fejleszt� Rt.
Publication of EE9700146A publication Critical patent/EE9700146A/et
Publication of EE04239B1 publication Critical patent/EE04239B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/02—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/64—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
EE9700146A 1995-11-02 1996-11-01 Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine EE04239B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
HU9503141A HU222994B1 (hu) 1995-11-02 1995-11-02 Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HU9603919 1996-02-09
HU9629820 1996-10-04
PCT/HU1996/000064 WO1997016439A1 (en) 1995-11-02 1996-11-01 Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof

Publications (2)

Publication Number Publication Date
EE9700146A EE9700146A (et) 1997-12-15
EE04239B1 true EE04239B1 (et) 2004-02-16

Family

ID=27270113

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700146A EE04239B1 (et) 1995-11-02 1996-11-01 Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine

Country Status (31)

Country Link
US (4) US6653326B1 (et)
EP (1) EP0801649B1 (et)
JP (2) JP4531865B2 (et)
KR (1) KR19980700976A (et)
CN (1) CN1152871C (et)
AT (1) ATE221880T1 (et)
AU (1) AU720195B2 (et)
BG (1) BG63944B1 (et)
BR (1) BR9607565B1 (et)
CA (1) CA2209167C (et)
CZ (1) CZ295562B6 (et)
DE (1) DE69622840T2 (et)
DK (1) DK0801649T3 (et)
EE (1) EE04239B1 (et)
ES (1) ES2176502T3 (et)
HR (1) HRP960508B1 (et)
HU (1) HU222994B1 (et)
IL (1) IL121126A (et)
MX (1) MX9704988A (et)
NO (1) NO321140B1 (et)
NZ (1) NZ320523A (et)
PL (1) PL195634B1 (et)
PT (1) PT801649E (et)
RS (1) RS49981B (et)
RU (1) RU2206320C2 (et)
SI (1) SI0801649T1 (et)
SK (1) SK284823B6 (et)
TR (1) TR199700574T1 (et)
UA (1) UA61050C2 (et)
WO (1) WO1997016439A1 (et)
ZA (1) ZA969249B (et)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT78139A (hu) * 1995-12-22 2000-11-28 BIOREX Kutató és Fejlesztő Rt. Készítmény, különösen a bőr öregedési folyamatainak mérséklésére
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
WO2000007580A2 (en) * 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
HU226617B1 (en) * 1998-12-14 2009-04-28 Cytrx Corp Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
HUP9900475D0 (en) * 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
FR2792832B1 (fr) * 1999-04-28 2002-05-10 Codif Internat Sa Procede de protection de la peau pour la prevenir de son vieillissement cellulaire
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
EP1406489A4 (en) * 2001-06-22 2005-08-24 Univ California EUKARYONTIC GENES WHICH ARE PARTICIPATED IN THE REGULATION OF THE LIFE AGES AS ADULTS
HUP0105205A2 (hu) * 2001-11-29 2003-08-28 BIOREX Kutató és Fejlesztő Rt. Metformint és egy hidroxilaminszármazékot tartalmazó, gyógyászati készítmény
PL371251A1 (en) * 2002-01-11 2005-06-13 Biorex Kutato Es Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
DK1616184T4 (en) * 2003-03-27 2018-08-13 Childrens Hospital Med Ct Method and kit for detecting early onset of renal tubular cell damage
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
RU2341522C2 (ru) * 2004-04-12 2008-12-20 Торрент Фармасьютикалз Лтд 2-пропен-1-оны в качестве индукторов hsp-70
WO2006006267A1 (ja) * 2004-07-07 2006-01-19 House Wellness Foods Corporation 抗ストレス剤
FR2880022B1 (fr) * 2004-12-24 2007-08-24 Mayoly Spindler Soc Par Action Nouveaux derives de la n-hydroxy-n'-phenyluree et de la n-hydroxy-n'-phenylthiouree et leur utilisation comme inhibiteurs de la synthese de la melanine
TW200831479A (en) * 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
AU2007328280A1 (en) * 2006-12-01 2008-06-12 Cytrx Corporation Hydroxylamine derivatives for the treatment of stroke
TW200901958A (en) * 2007-05-04 2009-01-16 Cytrx Corp Diabetic wound healing
BRPI0812997A2 (pt) * 2007-06-29 2014-12-23 Torrent Pharmaceuticals Ltd Novas piperidonas substituídas como indutores de hsp
EP3578195B1 (en) 2008-06-26 2023-08-09 Zevra Denmark A/S Use of hsp70 as a regulator of enzymatic activity
KR101645937B1 (ko) * 2008-11-11 2016-08-08 (주)아모레퍼시픽 육음외사에 의한 피부 변화를 정량하는 방법 및 이를 이용한 피부 개선 물질의 스크리닝 방법
WO2010058779A1 (ja) * 2008-11-18 2010-05-27 参天製薬株式会社 ピリジン－３－カルバルデヒド ｏ－（ピペリジン－１－イル－プロピル）－オキシム誘導体を有効成分として含有する網脈絡膜変性疾患の治療剤
US20110123473A1 (en) * 2009-11-26 2011-05-26 Basf Se Use of highly-branched polycarbonates in cosmetic and dermatological formulations
BR112013013143A2 (pt) 2010-11-30 2016-08-23 Orphazyme Aps composto, e, método de tratamento de uma doença de armazenagem lisossômica
KR101275264B1 (ko) * 2011-08-24 2013-06-17 포항공과대학교 산학협력단 샤프로닌 단백질의 조절 물질 탐색 방법
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
RU2495928C2 (ru) 2012-01-30 2013-10-20 Сергей Юрьевич Лешков Средство для стимуляции синтеза белков теплового шока hsp 70 в клетках человека и животных; косметическое средство для стимуляции репаративных процессов; косметическое средство для снижения побочных эффектов агрессивных косметологических процедур; биологически активная добавка; пищевой продукт; способ снижения побочных эффектов агрессивных косметологических процедур
HUE054957T2 (hu) 2014-09-15 2021-10-28 Orphazyme As Arimoklomol készítése
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
CA3021900A1 (en) 2016-04-29 2017-11-02 Orphazyme A/S Arimoclomol for treating glucocerebrosidase associated disorders
JP2020520947A (ja) 2017-05-24 2020-07-16 オーファザイム エー／エス 熱ショックタンパク質誘導因子および前頭側頭障害
CN108314630B (zh) * 2018-02-08 2020-11-06 广西民族大学 一种肟醚类衍生物及其制备方法与应用
AU2019276048A1 (en) 2018-05-28 2021-01-21 Zevra Denmark A/S Hsp70 protein levels in PBMC samples as biomarker for disease
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
CN110048418B (zh) * 2019-05-08 2023-03-24 辽宁工程技术大学 一种基于细胞-组织算法的微电网经济调度方法及装置
CN116075305A (zh) 2020-06-24 2023-05-05 柯姆药物丹麦股份公司 用于治疗戈谢病的阿瑞洛莫
CN112094878A (zh) * 2020-08-18 2020-12-18 周银根 一种二步酶提取香菇多糖的方法、香菇多糖提取物及其应用
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
IL303968A (en) 2020-12-24 2023-08-01 Zevra Denmark As Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations
IL311672A (en) * 2021-09-28 2024-05-01 Zevra Denmark As Dioxazines and their use in treatment of gba-related diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177578B (en) * 1976-08-27 1981-11-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives
DE2651083A1 (de) * 1976-11-09 1978-05-18 Hoechst Ag Neue o-alkylierte hydroxylamine, verfahren zu ihrer herstellung und ihre verwendung
HU207988B (en) 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
US5334600A (en) 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
HU216830B (hu) 1992-07-21 1999-09-28 BIOREX Kutató és Fejlesztő Rt., N-[2-Hidroxi-3-amino-propoxi]-amidok és -imidátok, valamint dioxazinok, eljárás ezek előállítására, és a vegyületeket tartalmazó gyógyszerkészítmények
KR100372312B1 (ko) * 1994-05-06 2003-05-09 바이오렉스 쿠타토 에스 페레즈토 알티 신규의히드록시믹산유도체,그를포함한약제학적조성물및그의제조방법
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
EE9700146A (et) 1997-12-15
US7148239B2 (en) 2006-12-12
HRP960508A2 (en) 1998-06-30
HRP960508B1 (en) 2004-10-31
CZ207297A3 (cs) 1998-03-18
PL195634B1 (pl) 2007-10-31
DE69622840T2 (de) 2003-04-30
ATE221880T1 (de) 2002-08-15
BR9607565B1 (pt) 2011-08-23
CN1152871C (zh) 2004-06-09
JP2009108048A (ja) 2009-05-21
EP0801649B1 (en) 2002-08-07
TR199700574T1 (xx) 1999-08-23
NO973059L (no) 1997-09-02
ES2176502T3 (es) 2002-12-01
ZA969249B (en) 1998-03-02
SK88197A3 (en) 1998-04-08
AU7326396A (en) 1997-05-22
RS49981B (sr) 2008-09-29
PT801649E (pt) 2002-12-31
UA61050C2 (en) 2003-11-17
CA2209167A1 (en) 1997-05-09
HUT76659A (en) 1997-10-28
HU9503141D0 (en) 1995-12-28
DK0801649T3 (da) 2002-12-02
NZ320523A (en) 2001-05-25
BG63944B1 (bg) 2003-07-31
AU720195B2 (en) 2000-05-25
KR19980700976A (et) 1998-04-30
US7745465B2 (en) 2010-06-29
JP4531865B2 (ja) 2010-08-25
US20100267711A1 (en) 2010-10-21
BG101713A (en) 1998-03-31
CN1177351A (zh) 1998-03-25
SI0801649T1 (en) 2002-12-31
CA2209167C (en) 2009-05-19
NO973059D0 (no) 1997-07-01
MX9704988A (es) 1998-07-31
WO1997016439A1 (en) 1997-05-09
DE69622840D1 (de) 2002-09-12
IL121126A0 (en) 1997-11-20
PL322015A1 (en) 1998-01-05
US20040019103A1 (en) 2004-01-29
EP0801649A2 (en) 1997-10-22
JPH10512590A (ja) 1998-12-02
CZ295562B6 (cs) 2005-08-17
NO321140B1 (no) 2006-03-27
HU222994B1 (hu) 2004-01-28
BR9607565A (pt) 1999-07-20
US20040067940A1 (en) 2004-04-08
IL121126A (en) 2002-07-25
RU2206320C2 (ru) 2003-06-20
YU58796A (sh) 1999-09-27
US6653326B1 (en) 2003-11-25
SK284823B6 (sk) 2005-12-01

Similar Documents

Publication Publication Date Title
EE04239B1 (et) Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
TR200000481T2 (tr) N-Alkonoilfenilalenin türevleri.
EE9800080A (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
ATE308327T1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
TR199902626T2 (xx) Enflamasyon tedavisi i�in ikameli benzopiran t�revleri.
ATE212351T1 (de) Androsten-derivate
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
FI940696A0 (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
BRPI0407652A (pt) método para acentuar a eficácia de um agente ativo, composição e método para produzir a composição
ATE221780T1 (de) Fenbendazolformulierungen
FI861329A (fi) Anvaendning av 4-(isoxazolyl)-tiazol-2-oxaminsyraderivat.
ATE206105T1 (de) Alkykendiamin di- oder tri-essigsäurederivate, verfahren zu ihrer herstellung und ihre verwendung in kosmetischen zusammensetzungen
AR009470A1 (es) COMPOSICIoN FARMACÉUTICA QUE CONTIENE CEPAS BACTERIANAS Y UTILES EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON O CAUSADAS POR ALTERACIONES EN EL METABOLISMO DE LOS ÁCIDOS BILIARES, Y USO DE LAS MISMAS.

Legal Events

Date Code Title Description
HD1A Correction of address
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20111101